Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Nov 7, 2014; 20(41): 15358-15366
Published online Nov 7, 2014. doi: 10.3748/wjg.v20.i41.15358
Published online Nov 7, 2014. doi: 10.3748/wjg.v20.i41.15358
Table 4 Prevalence of hepatitis B virus in our inflammatory bowel disease study vs in European studies
| Loras 2009 (study 1) | Chevaux 2010 (study 2) | Our IBD study | Study 1 vs our study(P value) | Study 2 vs our study(P value) | |
| Chronic HBV (HBsAg) | 0.7% | 0.95% | 1.8% | 0.070 | 0.159 |
| Exposure to HBV (Anti-HBc Ab) | 7.5% | 2.50% | 3.2% | 0.006 | 0.313 |
- Citation: Ben Musa R, Gampa A, Basu S, Keshavarzian A, Swanson G, Brown M, Abraham R, Bruninga K, Losurdo J, DeMeo M, Mobarhan S, Shapiro D, Mutlu E. Hepatitis B vaccination in patients with inflammatory bowel disease. World J Gastroenterol 2014; 20(41): 15358-15366
- URL: https://www.wjgnet.com/1007-9327/full/v20/i41/15358.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i41.15358